TVRD - Cara Therapeutics, Inc.

QQQ $ 605.04 $ 0.00 (0 %)

DIA $ 464.28 $ 0.00 (0 %)

SPY $ 667.27 $ 0.00 (0 %)

TLT $ 90.92 $ 0.00 (0 %)

GLD $ 390.02 $ 0.00 (0 %)

Previous Close

$ 6.64

Open

$ 6.91

Bid

$ 6.56 x 100

Ask

$ 6.64 x 37

Day's Range

-- - --

52 Week Range

$ 5.65 - $ 43.65

Volume

755,614

Average Volume

Market Cap

62.27M

Beta (5Y Monthly)

$ 1.08

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-14-2025	06-30-2025	10-Q
2	05-13-2025	03-31-2025	10-Q
3	03-11-2025	12-31-2024	10-K
4	11-14-2024	09-30-2024	10-Q
5	08-14-2024	06-30-2024	10-Q
6	05-13-2024	03-31-2024	10-Q
7	03-06-2024	12-31-2023	10-K
8	11-13-2023	09-30-2023	10-Q
9	08-07-2023	06-30-2023	10-Q
10	05-15-2023	03-31-2023	10-Q
11	03-06-2023	12-31-2022	10-K
12	11-07-2022	09-30-2022	10-Q
13	08-08-2022	06-30-2022	10-Q
14	05-09-2022	03-31-2022	10-Q
15	03-01-2022	12-31-2021	10-K
16	11-08-2021	09-30-2021	10-Q
17	08-09-2021	06-30-2021	10-Q
18	05-10-2021	03-31-2021	10-Q
19	02-25-2021	12-31-2020	10-K
20	11-09-2020	09-30-2020	10-Q
21	08-10-2020	06-30-2020	10-Q
22	05-11-2020	03-31-2020	10-Q
23	02-27-2020	12-31-2019	10-K
24	11-05-2019	09-30-2019	10-Q
25	08-07-2019	06-30-2019	10-Q
26	05-07-2019	03-31-2019	10-Q
27	03-12-2019	12-31-2018	10-K
28	11-06-2018	09-30-2018	10-Q
29	08-07-2018	06-30-2018	10-Q
30	05-09-2018	03-31-2018	10-Q
31	03-15-2018	12-31-2017	10-K
32	11-02-2017	09-30-2017	10-Q
33	08-03-2017	06-30-2017	10-Q
34	05-04-2017	03-31-2017	10-Q
35	03-10-2017	12-31-2016	10-K
36	11-04-2016	09-30-2016	10-Q
37	08-04-2016	06-30-2016	10-Q
38	05-05-2016	03-31-2016	10-Q
39	03-11-2016	12-31-2015	10-K
40	11-09-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Raymond James Downgrades Tvardi Therapeuti...
10/14/2025 14:11:28

Raymond James analyst Ryan Deschner downgrades Tvardi Therapeutics (NASDAQ:TVRD) from Outperform to Market Perform.

12 Health Care Stocks Moving In Tuesday's ...
10/14/2025 12:09:03

tvardi-therapeutics-lung-disease-candidate-fails-to-show-any-clinical-benefit-stock-sinks

Tvardi Therapeutics' Lung Disease Candidat...
10/13/2025 18:23:45

Tvardi Therapeutics stock falls as Phase 2 IPF trial of TTI-101 shows no significant FVC improvement, with high variability and...

gold-rises-over-3-tvardi-therapeutics-shares-plunge

Gold Rises Over 3%; Tvardi Therapeutics Sh...
10/13/2025 17:12:39

12 Health Care Stocks Moving In Monday's I...
10/13/2025 17:06:02

BTIG Maintains Buy on Tvardi Therapeutics,...
10/13/2025 15:37:26

BTIG analyst Julian Harrison maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and lowers the price target from $55 to ...

dow-surges-1-fastenal-shares-fall-after-q3-results

Dow Surges 1%; Fastenal Shares Fall After ...
10/13/2025 13:55:08

Barclays Initiates Coverage On Tvardi Ther...
10/13/2025 12:14:49

Barclays analyst Etzer Darout initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Overweight rating and announces...

12 Health Care Stocks Moving In Monday's P...
10/13/2025 12:08:59

Tvardi Therapeutics Said Preliminary Data ...
10/13/2025 11:32:36

The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI-101 alone or in ...

Tvardi Therapeutics Says On Track For Mult...
08/14/2025 21:07:01

Tvardi Therapeutics Q2 EPS $(1.00) Misses ...
08/14/2025 20:33:23

Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of...

Raymond James Initiates Coverage On Tvardi...
07/14/2025 14:50:50

Raymond James analyst Ryan Deschner initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Outperform rating and ann...

Cantor Fitzgerald Initiates Coverage On Tv...
07/11/2025 12:00:31

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Overweight rating a...

recently-listed-tvardi-therapeutics-lead-drug-positioned-to-drive-broad-improvement-analyst-sees-over-150-stock-upside

Recently Listed Tvardi Therapeutics' Lead ...
06/12/2025 19:07:56

Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway int...

this-modine-manufacturing-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday

This Modine Manufacturing Analyst Begins C...
06/12/2025 12:38:11

Piper Sandler Initiates Coverage On Tvardi...
06/12/2025 09:27:44

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Overweight rating and an...

Tvardi Therapeutics Files Prospectus Relat...
05/30/2025 20:18:24

-SEC Filing

Tvardi Therapeutics Completes Enrollment F...
05/27/2025 12:06:32

Topline data from the REVERT IPF trial anticipated in 4Q 2025Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clin...

Oppenheimer Initiates Coverage On Tvardi T...
05/21/2025 15:13:36

Oppenheimer analyst Jay Olson initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Outperform rating and announces...